welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Desmoid Tumors — Dangerous when not Treated as Cancerhttps://www.youtube.com/watch?v=gPcEJ8kA...
-
Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC)Hereditary forms of colorectal cancer ac...
-
Coxib-inhibition of Duodenal Polyp Growth in FAPPreliminary data indicate a protective e...
-
Pancreatic Enzyme Replacement TherapyIf you have chronic pancreatitis, a panc...
-
V-blog – Update!!! 2013 the year of the Desmoid!https://www.youtube.com/watch?v=HpyUTBLX...
-
A Prospective Multicenter Phase II Study of Sunitinib in Patients With Advanced Aggressive FibromatosisSeveral studies have reported that imati...
-
Prophylactic Colectomy: Rationale, Indications, and ApproachDiscerning the genetics of hereditary co...